Elixirgen Therapeutics announced that it has entered into an exclusive three-year research collaboration agreement with Taisho Pharmaceutical Co.

The partnership will leverage Elixirgen Therapeutics' proprietary ZSCAN4 therapy platform to advance potential treatments of ageing-associated diseases in humans. Elixirgen Therapeutics is currently performing a Phase I/II clinical trial applying its ZSCAN4 therapy platform in telomere biology disorders with bone marrow failure, a rare, orphan disease, at Cincinnati Children's Hospital Medical Center.

Taisho Pharmaceutical will bring its experience and expertise in the research and development of therapeutic products to the collaboration.

Akihiro Ko, CEO of Elixirgen Therapeutics, said, "We are pleased to collaborate with Taisho Pharmaceutical, a prominent leader in healthcare and pharmaceuticals, to address aging-associated diseases, which are a major focus of our company."